CliffBio
small molecule

EMBOLEX

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameEMBOLEX
Active ingredientDIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE
Strength0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalNovember 1984
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.